Q4 features revenues of $18.5 million ; 2020 revenues reach $27.5 million driven by COVID-19 testing Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system Conference call begins at 4:30 p.m.
- Fourth quarter revenues reached a record $1.8 million, up 108% over the fourth quarter of 2018 and up 17% over the third quarter of 2019 - Fourth quarter commercial revenues increased 94% over the fourth quarter of 2018 and increased 11% over the third quarter of 2019 - Fourth quarter cost of
Progress made implementing the Company's commercial strategy highlighted by 7% sequential quarterly growth in billable test volume in the fourth quarter of 2018 compared to the third quarter of 2018 Capitalized to deliver on key initiatives in 2019 including growth from pathology partnership and
2017 revenues increased 57% due to higher reimbursement for Target Selector™ liquid biopsy tests and the impact of conversion to accrual-based revenue recognition Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , March 28, 2018 /PRNewswire/ -- Biocept, Inc.
Revenues increased 58% sequentially to a record highCommercial sample volume more than doubled versus prior year period9 consecutive quarters of growth in total sample volumeCompany to host conference call at 4:30 p.m. Eastern time today
Test growth and improvements in billing and collections drive more than an 8-fold increase in revenues year-over-yearConference call begins at 11:00 a.m. Eastern time today
Billable sample volume increases 280% year-over-year and marks the fourth consecutive quarter of double-digit sequential growthConference call begins at 4:30 p.m. Eastern time today
Billable sample volume increases by more than 30% for third consecutive quarter reaching full-year 2015 total of 1,8242015 revenues grow more than three-foldConference call begins at 4:30 p.m. Eastern time today
To be a shareholder of record, investors are advised to own Biocept stock by 4:00 PM ET, Thursday, July 19, 2018 to account for T+2 settlement timing Record date established as Monday, July 23, 2018 SAN DIEGO , July 19, 2018 /PRNewswire/ -- Biocept, Inc.
New patents further expand the Company's intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells (CTCs), to aid in the management of patients with cancer Biocept now has 36 issued patents globally covering its novel liquid biopsy
